反应性骨髓增生与髓系介导的免疫抑制的发生：对过继细胞治疗的影响。
Reactive myelopoiesis and the onset of myeloid-mediated immune suppression: Implications for adoptive cell therapy.
机构信息
Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
出版信息
Cell Immunol. 2021 Mar;361:104277. doi: 10.1016/j.cellimm.2020.104277. Epub 2020 Dec 26.
Abstract
Adoptive T cell therapy (ACT) in combination with lymphodepleting chemotherapy is an effective strategy to induce the eradication of cancer, providing long-term regressions in patients. However, only a minority of patients that receive ACT with tumor-specific T cells exhibit durable benefit. Thus, there is an urgent need to characterize mechanisms of resistance and define strategies to alleviate immunosuppression in the context of ACT in cancer. This article reviews the importance of lymphodepleting regimens in promoting the optimal engraftment and expansion of T cells in hosts after adoptive transfer. In addition, we discuss the role of concomitant immunosuppression and the accumulation of myeloid derived suppressor cells (MDSCs) during immune recovery after lymphodepleting regimens and mobilization regimens.
摘要
过继性 T 细胞疗法（ACT）与淋巴细胞耗竭化疗相结合是一种有效策略，可以诱导癌症的消除，为患者提供长期缓解。然而，只有少数接受肿瘤特异性 T 细胞的 ACT 的患者表现出持久的益处。因此，迫切需要确定抵抗机制，并定义在癌症的 ACT 背景下减轻免疫抑制的策略。本文综述了淋巴细胞耗竭方案在促进过继转移后宿主中 T 细胞的最佳植入和扩增中的重要性。此外，我们还讨论了在淋巴细胞耗竭方案和动员方案后免疫恢复期间伴随的免疫抑制和髓样来源抑制细胞（MDSCs）积累的作用。
相似文献
1
Reactive myelopoiesis and the onset of myeloid-mediated immune suppression: Implications for adoptive cell therapy.反应性骨髓增生与髓系介导的免疫抑制的发生：对过继细胞治疗的影响。
Cell Immunol. 2021 Mar;361:104277. doi: 10.1016/j.cellimm.2020.104277. Epub 2020 Dec 26.
2
Reactive Myelopoiesis Triggered by Lymphodepleting Chemotherapy Limits the Efficacy of Adoptive T Cell Therapy.淋巴耗竭化疗引发的反应性骨髓增生限制了过继性 T 细胞治疗的疗效。
Mol Ther. 2020 Oct 7;28(10):2252-2270. doi: 10.1016/j.ymthe.2020.06.025. Epub 2020 Jun 24.
3
IFN regulatory factor 8 represses GM-CSF expression in T cells to affect myeloid cell lineage differentiation.干扰素调节因子8抑制T细胞中粒细胞-巨噬细胞集落刺激因子的表达，从而影响髓系细胞谱系分化。
J Immunol. 2015 Mar 1;194(5):2369-79. doi: 10.4049/jimmunol.1402412. Epub 2015 Feb 2.
4
Efficient T cell adoptive transfer in lymphoreplete hosts mediated by transient activation of Stat5 signaling.通过短暂激活 Stat5 信号转导途径在淋巴组织丰富的宿主体内实现高效 T 细胞过继转移。
Mol Ther. 2023 Sep 6;31(9):2591-2599. doi: 10.1016/j.ymthe.2023.07.015. Epub 2023 Jul 21.
5
The DNA methyltransferase inhibitor, guadecitabine, targets tumor-induced myelopoiesis and recovers T cell activity to slow tumor growth in combination with adoptive immunotherapy in a mouse model of breast cancer.DNA 甲基转移酶抑制剂，地西他滨，通过靶向肿瘤诱导的骨髓细胞生成，并与过继免疫疗法相结合，恢复 T 细胞活性，从而减缓乳腺癌小鼠模型中的肿瘤生长。
BMC Immunol. 2020 Feb 27;21(1):8. doi: 10.1186/s12865-020-0337-5.
6
T-cell-Secreted TNFα Induces Emergency Myelopoiesis and Myeloid-Derived Suppressor Cell Differentiation in Cancer.T 细胞分泌的 TNFα 诱导癌症中的紧急髓系生成和髓系来源的抑制细胞分化。
Cancer Res. 2019 Jan 15;79(2):346-359. doi: 10.1158/0008-5472.CAN-17-3026. Epub 2018 Nov 2.
7
Analysis of therapeutic potential of monocytic myeloid-derived suppressor cells in cardiac allotransplantation.分析单核细胞来源的髓样抑制细胞在心脏同种异体移植中的治疗潜力。
Transpl Immunol. 2021 Aug;67:101405. doi: 10.1016/j.trim.2021.101405. Epub 2021 May 8.
8
Targeting myeloid-derived suppressor cells with gemcitabine to enhance efficacy of adoptive cell therapy in bladder cancer.用吉西他滨靶向髓源性抑制细胞增强膀胱癌过继细胞治疗的疗效。
Front Immunol. 2023 Oct 12;14:1275375. doi: 10.3389/fimmu.2023.1275375. eCollection 2023.
9
Synergistic effect of adoptive immunotherapy and docetaxel inhibits tumor growth in a mouse model.过继免疫疗法和多西他赛的协同作用抑制了小鼠模型中的肿瘤生长。
Cell Immunol. 2020 Feb;348:104036. doi: 10.1016/j.cellimm.2019.104036. Epub 2019 Dec 31.
10
Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy.抑制髓源抑制性细胞的迁移可增强 T 细胞免疫治疗。
JCI Insight. 2019 Apr 4;4(7). doi: 10.1172/jci.insight.126853.
引用本文的文献
1
The endogenous T cell landscape is reshaped by CAR-T cell therapy and predicts treatment response in multiple myeloma.嵌合抗原受体T细胞（CAR-T）疗法重塑内源性T细胞格局，并可预测多发性骨髓瘤的治疗反应。
Leukemia. 2025 Sep 19. doi: 10.1038/s41375-025-02766-5.
2
Overcoming resistant cancerous tumors through combined photodynamic and immunotherapy (photoimmunotherapy).通过联合光动力疗法和免疫疗法（光免疫疗法）攻克耐药性癌性肿瘤。
Front Immunol. 2025 Jul 17;16:1633953. doi: 10.3389/fimmu.2025.1633953. eCollection 2025.
3
Cancer immunotherapy and its facilitation by nanomedicine.癌症免疫疗法及其纳米医学促进作用。
Biomark Res. 2024 Aug 3;12(1):77. doi: 10.1186/s40364-024-00625-6.
4
Immunosuppressive regulatory cells in cancer immunotherapy: restrain or modulate?癌症免疫治疗中的免疫抑制调节细胞：抑制还是调节？
Hum Cell. 2024 Jul;37(4):931-943. doi: 10.1007/s13577-024-01083-w. Epub 2024 May 30.
5
Reactive myelopoiesis and FX-expressing macrophages triggered by chemotherapy promote cancer lung metastasis.化疗引发的反应性骨髓生成和 FX 表达的巨噬细胞促进癌症肺转移。
JCI Insight. 2023 May 8;8(9):e167499. doi: 10.1172/jci.insight.167499.
6
Tumor MHC class I expression alters cancer-associated myelopoiesis driven by host NK cells.肿瘤 MHC I 类分子的表达改变了由宿主 NK 细胞驱动的癌症相关髓系细胞生成。
J Immunother Cancer. 2022 Oct;10(10). doi: 10.1136/jitc-2022-005308.
本文引用的文献
1
Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19.血清钙卫蛋白和异常髓系细胞亚群可区分 COVID-19 重症与轻症。
Cell. 2020 Sep 17;182(6):1401-1418.e18. doi: 10.1016/j.cell.2020.08.002. Epub 2020 Aug 5.
2
Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment.严重的 COVID-19 以髓系细胞失调为特征。
Cell. 2020 Sep 17;182(6):1419-1440.e23. doi: 10.1016/j.cell.2020.08.001. Epub 2020 Aug 5.
3
Different MDSC Activity of G-CSF/Dexamethasone Mobilized Neutrophils: Benefits to the Patient?粒细胞集落刺激因子/地塞米松动员的中性粒细胞的不同髓系来源抑制细胞活性：对患者有益吗？
Front Oncol. 2020 Jul 21;10:1110. doi: 10.3389/fonc.2020.01110. eCollection 2020.
4
Can we harness the microbiota to enhance the efficacy of cancer immunotherapy?我们能否利用微生物组来提高癌症免疫疗法的疗效？
Nat Rev Immunol. 2020 Sep;20(9):522-528. doi: 10.1038/s41577-020-0374-6. Epub 2020 Jul 13.
5
Reactive Myelopoiesis Triggered by Lymphodepleting Chemotherapy Limits the Efficacy of Adoptive T Cell Therapy.淋巴耗竭化疗引发的反应性骨髓增生限制了过继性 T 细胞治疗的疗效。
Mol Ther. 2020 Oct 7;28(10):2252-2270. doi: 10.1016/j.ymthe.2020.06.025. Epub 2020 Jun 24.
6
Durable and controlled depletion of neutrophils in mice.在小鼠中持久且可控的中性粒细胞耗竭。
Nat Commun. 2020 Jun 2;11(1):2762. doi: 10.1038/s41467-020-16596-9.
7
Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity.采用表达树突状细胞生长因子 Flt3L 的 T 细胞过继细胞疗法可诱导表位扩展和抗肿瘤免疫。
Nat Immunol. 2020 Aug;21(8):914-926. doi: 10.1038/s41590-020-0676-7. Epub 2020 May 18.
8
Comprehensive single institute experience with melanoma TIL: Long term clinical results, toxicity profile, and prognostic factors of response.黑色素瘤 TIL 的综合单中心经验：长期临床结果、毒性特征和反应的预后因素。
Mol Carcinog. 2020 Jul;59(7):736-744. doi: 10.1002/mc.23193. Epub 2020 Apr 6.
9
Tumor-Derived Retinoic Acid Regulates Intratumoral Monocyte Differentiation to Promote Immune Suppression.肿瘤衍生的视黄酸调节肿瘤内单核细胞分化以促进免疫抑制。
Cell. 2020 Mar 19;180(6):1098-1114.e16. doi: 10.1016/j.cell.2020.02.042. Epub 2020 Mar 12.
10
Defining the emergence of myeloid-derived suppressor cells in breast cancer using single-cell transcriptomics.利用单细胞转录组学定义乳腺癌中髓系来源抑制细胞的出现。
Sci Immunol. 2020 Feb 21;5(44). doi: 10.1126/sciimmunol.aay6017.
Zotero 插件